Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GALT - Galectin Therapeutics Inc


IEX Last Trade
2.7
-0.040   -1.481%

Share volume: 190,705
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.74
-0.04
-1.46%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 3%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
16.67%
1 Month
9.78%
3 Months
-0.92%
6 Months
42.59%
1 Year
56.69%
2 Year
41.84%
Key data
Stock price
$2.70
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.56 - $4.27
52 WEEK CHANGE
$0.53
MARKET CAP 
167.840 M
YIELD 
N/A
SHARES OUTSTANDING 
62.278 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$157,724
AVERAGE 30 VOLUME 
$123,294
Company detail
CEO: Harold Shlevin
Region: US
Website: http://galectintherapeutics.com/
Employees: 52
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Recent news